| 2020-YEO-68868 | |
| Researchers at Purdue University have developed a soft, flexible non-cationic nanocapsule for systemic delivery of RNA therapeutics. Compared to non-viral vectors, typically based on cationic lipids or polymers, the Purdue technology, dubbed "Nanosac", performs well in the anionic environment prevalent in the body. Nanosac showed efficient cellular uptake in cancer cells. Nanosac was taken up less by macrophages and penetrated more into tumor tissues than hard nanoparticle counterparts. Nanosac was also non-toxic to cells. In a mouse colon cancer model using CT26 cells, siRNA targeting the PD-1/PD-L1 immune checkpoint interaction was delivered via Nanosac systemically, and the treated group showed a significant attenuation in tumor growth. Advantages: -Enables systemic delivery of RNA therapeutics -Avoids toxicity and nonspecific protein adsorption -Enhanced transvascular and interstitial delivery -Improved intratumoral penetration -Safer, more scalable, less heterogeneous, and less immunogenic than cell-derived vesicles Potential Applications: -Delivery of RNA-based Gene Therapy Technology Validation: Cellular uptake and toxicity were evaluated in cell culture, and efficacy of a therapeutic delivered by Nanosac was validated in a mouse model. Related Publications: Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors ACS Nano 2021, 15, 3, 4576–4593 https://doi.org/10.1021/acsnano.0c08694 |
|
|
|
|
May 31, 2023
NATL-Patent
South Korea
(None)
(None)
May 2, 2023
NATL-Patent
United States
(None)
(None)
Oct 27, 2021
PCT-Gov. Funding
WO
(None)
(None)
Oct 27, 2021
NATL-Patent
Europe
(None)
(None)
Oct 27, 2021
NATL-Patent
Canada
(None)
(None)
Nov 6, 2020
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
